GGT5 and invasive breast carcinoma: In contrast, significantly decreased GGT5 expression was noticed in invasive breast carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), and uterine corpus endometrial carcinoma (UCEC) (p < 0.05) (Figure 1A).